<DOC>
	<DOC>NCT01161173</DOC>
	<brief_summary>This observational study will evaluate the safety and efficacy of Tarceva (erlotinib) in routine clinical practice as second-line treatment in patients with recurrent or metastatic non-small dell lung cancer (NSCLC). Data will be collected from patients who have received 1 course of standard systemic chemotherapy, experienced disease progression, and who are receiveingTarceva in a second-line setting. Patients will also be followed through third-line treatment if there is disease progression on Tarceva therapy.</brief_summary>
	<brief_title>An Observational Study of Tarceva (Erlotinib) in Routine Daily Clinical Practice as Second Line Treatment in Patients With Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Adult patients â‰¥ 18 years of age. Written informed consent. Recurrent or metastatic, Stage III or IV nonsmall cell lung cancer (NSCLC). Measurable disease (Response Evaluation Criteria In Solid Tumors). Eastern Cooperative Oncology Group (ECOG) performance status of 02. Prior course of standard systemic chemotherapy. Contraindications to treatment with Tarceva.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>